Guardian Pharmacy Services to Release Q4 and Full-Year 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy GRDN?
Source: Businesswire
- Earnings Release Schedule: Guardian Pharmacy Services will announce its fourth quarter and full-year 2025 financial results after market close on March 11, 2026, providing investors with critical financial performance data to assess the company's operational status.
- Conference Call Details: Management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results, allowing investors to participate via audio webcast or designated phone numbers, ensuring transparency and timeliness of information.
- Replay Availability: A replay of the call will be available for approximately 60 days after its conclusion, enabling investors who could not attend in real-time to access important information, thereby enhancing communication between the company and its investors.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, serving approximately 204,000 residents.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRDN
Wall Street analysts forecast GRDN stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 37.090
Low
34.00
Averages
34.50
High
35.00
Current: 37.090
Low
34.00
Averages
34.50
High
35.00
About GRDN
Guardian Pharmacy Services, Inc. is a long-term care pharmacy services company. Through its locally based business model, it partners with long-term care facilities (LTCF0073) to deliver medications, and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its Guardian Compass platform offers insights to enhance efficiency for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Guardian Pharmacy Services to Release Q1 2026 Financial Results
- Earnings Release Announcement: Guardian Pharmacy Services has announced that it will release its Q1 2026 financial results after market close on May 6, 2026, with management hosting a conference call at 4:30 p.m. Eastern Time, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The conference call will be available via audio webcast, with investors able to participate through a designated link or by dialing a dedicated number for U.S. and Canadian participants, while international participants can access the call through provided international numbers, ensuring broad investor engagement and information dissemination.
- Company Overview: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, highlighting its significant position in the industry.
- Network Expansion: As of December 31, 2025, Guardian operates 61 pharmacies, 54 of which are full-service, serving approximately 205,000 residents, indicating the company's ongoing growth in the long-term care market and its commitment to customer service.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
Guardian Pharmacy Shares Surge 9.1% Amid Strong Investor Confidence
- Stock Performance: Guardian Pharmacy Services (GRDN) shares surged 9.1% in the last trading session to close at $37.25, reflecting heightened investor confidence in its product portfolio and notable trading volume exceeding typical levels.
- Earnings Expectations: The company is expected to report quarterly earnings of $0.24 per share, representing a year-over-year increase of 14.3%, with revenues projected at $329.68 million, up 0.1% from the previous year, indicating sustained competitiveness in the long-term care pharmacy market.
- Estimate Revision Trend: Over the past 30 days, the consensus EPS estimate for GRDN has been revised 4.8% higher, and such positive revision trends are often correlated with stock price appreciation, suggesting potential future gains.
- Market Position: GRDN currently holds a Zacks Rank of #1 (Strong Buy), further reflecting market recognition of its position and growth potential within the medical drugs industry.
See More
Five Stocks Added to Zacks Rank #1 (Strong Buy) List
- National Energy Services: National Energy Services Reunited Corp. (NESR) has seen a 6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days, indicating growing market confidence in its profitability and potential stock price appreciation.
- Blue Bird Corporation: Blue Bird Corporation (BLBD) experienced an 8.3% rise in the Zacks Consensus Estimate for its current year earnings during the same period, reflecting strong demand in the school bus manufacturing sector, which is expected to enhance its market share.
- Permian Resources: Permian Resources Corporation (PR) saw a significant 53.1% increase in the Zacks Consensus Estimate for its current year earnings over the past 60 days, showcasing robust performance in the oil and gas industry that may attract more investor interest.
- Lifetime Brands: Lifetime Brands, Inc. (LCUT) recorded a 35.6% rise in the Zacks Consensus Estimate for its current year earnings in the same timeframe, indicating strong market demand for its kitchenware products, which is likely to drive company growth.
See More
Investment Thesis on Guardian Pharmacy Services: A Bullish Outlook
- Market Share Advantage: Guardian Pharmacy Services holds approximately 14-15% market share in the assisted living facility (ALF) segment, being the largest player, which provides a clear runway for both organic and inorganic growth, further solidifying its market position.
- Operational Efficiency: Operating 56 facilities across 38 states with a decentralized model empowers local presidents with P&L responsibility while HQ supports purchasing, HR, and technology, enhancing employee retention and service consistency, thus creating significant barriers to entry for competitors.
- Strong Growth Potential: Despite short-term margin pressure from recently acquired or opened facilities, long-term EBITDA growth is projected in the mid-to-high teens, with EPS growth exceeding 20-25%, supported by operational leverage and capital-light investments.
- Stable Revenue Source: The company’s revenue is predominantly derived from Medicare Part D, a stable and economically insensitive source, combined with high switching costs and strong relationships with facility staff, positioning Guardian for sustained growth in the long-term care pharmacy market.
See More
Guardian Pharmacy Services Raises $186M in Upsized Public Offering
- Fundraising Success: Guardian Pharmacy Services raised approximately $186 million by selling 6 million Class A shares at $31 each, reflecting strong market demand for its stock.
- Share Structure: Of the total shares issued, about 4.98 million were sold by existing holders, while approximately 1.02 million were issued through a non-dilutive secondary offering, ensuring stability in the company's equity structure.
- Underwriter Option: The underwriters have a 30-day option to purchase up to 900,000 additional shares, which enhances liquidity and investor confidence in the stock.
- Repurchase Plan: Guardian plans to use all net proceeds from the offering to repurchase 1.02 million Class A shares, expected to close by March 24, 2026, thereby maintaining the existing shareholder equity without dilution.
See More
Guardian Pharmacy Services to Release Q1 2026 Financial Results
- Earnings Release Announcement: Guardian Pharmacy Services has announced that it will release its Q1 2026 financial results after market close on May 6, 2026, with management hosting a conference call at 4:30 p.m. Eastern Time, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The conference call will be available via audio webcast, with investors able to participate through a designated link or by dialing a dedicated number for U.S. and Canadian participants, while international participants can access the call through provided international numbers, ensuring broad investor engagement and information dissemination.
- Company Overview: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, highlighting its significant position in the industry.
- Network Expansion: As of December 31, 2025, Guardian operates 61 pharmacies, 54 of which are full-service, serving approximately 205,000 residents, indicating the company's ongoing growth in the long-term care market and its commitment to customer service.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
Guardian Pharmacy Shares Surge 9.1% Amid Strong Investor Confidence
- Stock Performance: Guardian Pharmacy Services (GRDN) shares surged 9.1% in the last trading session to close at $37.25, reflecting heightened investor confidence in its product portfolio and notable trading volume exceeding typical levels.
- Earnings Expectations: The company is expected to report quarterly earnings of $0.24 per share, representing a year-over-year increase of 14.3%, with revenues projected at $329.68 million, up 0.1% from the previous year, indicating sustained competitiveness in the long-term care pharmacy market.
- Estimate Revision Trend: Over the past 30 days, the consensus EPS estimate for GRDN has been revised 4.8% higher, and such positive revision trends are often correlated with stock price appreciation, suggesting potential future gains.
- Market Position: GRDN currently holds a Zacks Rank of #1 (Strong Buy), further reflecting market recognition of its position and growth potential within the medical drugs industry.
See More
Five Stocks Added to Zacks Rank #1 (Strong Buy) List
- National Energy Services: National Energy Services Reunited Corp. (NESR) has seen a 6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days, indicating growing market confidence in its profitability and potential stock price appreciation.
- Blue Bird Corporation: Blue Bird Corporation (BLBD) experienced an 8.3% rise in the Zacks Consensus Estimate for its current year earnings during the same period, reflecting strong demand in the school bus manufacturing sector, which is expected to enhance its market share.
- Permian Resources: Permian Resources Corporation (PR) saw a significant 53.1% increase in the Zacks Consensus Estimate for its current year earnings over the past 60 days, showcasing robust performance in the oil and gas industry that may attract more investor interest.
- Lifetime Brands: Lifetime Brands, Inc. (LCUT) recorded a 35.6% rise in the Zacks Consensus Estimate for its current year earnings in the same timeframe, indicating strong market demand for its kitchenware products, which is likely to drive company growth.
See More
Investment Thesis on Guardian Pharmacy Services: A Bullish Outlook
- Market Share Advantage: Guardian Pharmacy Services holds approximately 14-15% market share in the assisted living facility (ALF) segment, being the largest player, which provides a clear runway for both organic and inorganic growth, further solidifying its market position.
- Operational Efficiency: Operating 56 facilities across 38 states with a decentralized model empowers local presidents with P&L responsibility while HQ supports purchasing, HR, and technology, enhancing employee retention and service consistency, thus creating significant barriers to entry for competitors.
- Strong Growth Potential: Despite short-term margin pressure from recently acquired or opened facilities, long-term EBITDA growth is projected in the mid-to-high teens, with EPS growth exceeding 20-25%, supported by operational leverage and capital-light investments.
- Stable Revenue Source: The company’s revenue is predominantly derived from Medicare Part D, a stable and economically insensitive source, combined with high switching costs and strong relationships with facility staff, positioning Guardian for sustained growth in the long-term care pharmacy market.
See More
Guardian Pharmacy Services Raises $186M in Upsized Public Offering
- Fundraising Success: Guardian Pharmacy Services raised approximately $186 million by selling 6 million Class A shares at $31 each, reflecting strong market demand for its stock.
- Share Structure: Of the total shares issued, about 4.98 million were sold by existing holders, while approximately 1.02 million were issued through a non-dilutive secondary offering, ensuring stability in the company's equity structure.
- Underwriter Option: The underwriters have a 30-day option to purchase up to 900,000 additional shares, which enhances liquidity and investor confidence in the stock.
- Repurchase Plan: Guardian plans to use all net proceeds from the offering to repurchase 1.02 million Class A shares, expected to close by March 24, 2026, thereby maintaining the existing shareholder equity without dilution.
See More
